Abstract 11135: Ventricular Arrhythmia Outcomes Following Immunosuppression Initiation in Cardiac Sarcoidosis
Abstract
Introduction: Cardiac sarcoidosis (CS) is an inflammatory cardiomyopathy associated with life-threatening ventricular arrhythmias and heart failure. Although immunosuppressive therapy (IST) remains the cornerstone of treatment, its impact on ventricular arrhythmia risk is not well defined, particularly in the era of combination and steroid-sparing regimens. Objectives: To evaluate the incidence, temporal distribution, and predictors of ventricular arrhythmias following initiation of IST in adults with CS. Methods: This single-center retrospective cohort study included 215 adults with definite or probable CS who initiated a new IST regimen between 2010 and 2024. Baseline clinical, echocardiogram, and treatment characteristics were abstracted. The primary endpoint was a major arrhythmic event (MAE), defined as sustained ventricular tachycardia (VT), ventricular fibrillation (VF), appropriate implantable cardioverter-defibrillator therapy, or cardiac arrest occurring after IST initiation. Cox proportional hazards regression was used to identify predictors of post-IST MAEs. Results: The median age was 58 years, and 60% were male. Before IST initiation, 14% had coronary artery disease, 21% had a history of sustained VT/VF, and 26% were receiving antiarrhythmic therapy (amiodarone, n=33; sotalol, n=17; mexiletine, n=5; flecainide, n=1). Median left ventricular ejection fraction was 52%. Most patients (195/215, 91%) initiated combination IST (≥2 agents), including 191 (89%) who received prednisone plus a nonsteroidal IST agent. During a median follow-up of 5.0 years (IQR 2.5-7.6), 68 patients (32%) experienced a MAE, with a median time to first event of 9.5 months (IQR 3.2-30.3) ( Figure ). Arrhythmic risk was concentrated early after IST initiation, with 54% of first MAEs occurring within 12 months and 74% within 24 months. Cardiac arrest occurred in 7 patients (3%). On multivariable analysis, a history of sustained VT/VF was the only independent predictor of post-IST MAEs (HR 6.87, 95% CI 3.20-14.75; p<0.001). Baseline antiarrhythmic drug use was not independently associated with subsequent MAEs (HR 1.59, 95% CI 0.78-3.22; p=0.20). Conclusion: In this contemporary cohort of adults with CS initiating IST, most commonly with combination regimens, ventricular arrhythmias were common and occurred predominantly within the first 2 years after treatment initiation. These findings highlight the need for close arrhythmic surveillance early after IST initiation, particularly among patients with a history of sustained ventricular arrhythmias, regardless of baseline antiarrhythmic drug therapy.